University of Notre Dame DU Lac reduced its stake in shares of Humana Inc (NYSE:HUM) by 10.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,438 shares of the insurance provider’s stock after selling 1,027 shares during the quarter. University of Notre Dame DU Lac’s holdings in Humana were worth $2,856,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. Stratos Wealth Partners LTD. acquired a new position in Humana during the third quarter worth about $108,000. Honkamp Krueger Financial Services Inc. acquired a new stake in shares of Humana in the third quarter valued at approximately $108,000. Sun Life Financial INC grew its position in shares of Humana by 120.7% in the second quarter. Sun Life Financial INC now owns 373 shares of the insurance provider’s stock valued at $111,000 after purchasing an additional 204 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its position in shares of Humana by 2,984.6% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 401 shares of the insurance provider’s stock valued at $119,000 after purchasing an additional 388 shares during the last quarter. Finally, Smithfield Trust Co. grew its position in shares of Humana by 531.2% in the third quarter. Smithfield Trust Co. now owns 486 shares of the insurance provider’s stock valued at $165,000 after purchasing an additional 409 shares during the last quarter. Institutional investors own 92.90% of the company’s stock.

Shares of NYSE HUM opened at $324.47 on Wednesday. Humana Inc has a 1 year low of $242.00 and a 1 year high of $355.88. The company has a market cap of $45.20 billion, a P/E ratio of 27.71, a PEG ratio of 1.58 and a beta of 0.99. The company has a current ratio of 1.68, a quick ratio of 1.68 and a debt-to-equity ratio of 0.45.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, November 7th. The insurance provider reported $4.58 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $4.29 by $0.29. Humana had a net margin of 2.70% and a return on equity of 19.10%. The firm had revenue of $14.21 billion for the quarter, compared to analyst estimates of $13.97 billion. During the same quarter last year, the business earned $3.39 earnings per share. Sell-side analysts anticipate that Humana Inc will post 14.43 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, January 25th. Investors of record on Monday, December 31st will be given a dividend of $0.50 per share. The ex-dividend date is Friday, December 28th. This represents a $2.00 dividend on an annualized basis and a yield of 0.62%. Humana’s dividend payout ratio (DPR) is currently 11.96%.

Several research firms have recently commented on HUM. Zacks Investment Research lowered shares of Humana from a “buy” rating to a “hold” rating in a research report on Monday. Morgan Stanley increased their price target on shares of Humana from $400.00 to $418.00 and gave the company a “buy” rating in a research report on Thursday, November 8th. BMO Capital Markets set a $390.00 price target on shares of Humana and gave the company a “buy” rating in a research report on Thursday, November 8th. Royal Bank of Canada increased their price target on shares of Humana from $318.00 to $349.00 and gave the company a “sector perform” rating in a research report on Thursday, November 8th. Finally, Credit Suisse Group increased their price target on shares of Humana from $370.00 to $390.00 and gave the company an “outperform” rating in a research report on Thursday, November 8th. Seven research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $352.30.

In related news, CEO Bruce D. Broussard sold 18,000 shares of the firm’s stock in a transaction that occurred on Monday, September 10th. The shares were sold at an average price of $328.66, for a total transaction of $5,915,880.00. Following the sale, the chief executive officer now owns 71,085 shares in the company, valued at $23,362,796.10. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Roy A. Beveridge sold 4,622 shares of the firm’s stock in a transaction that occurred on Thursday, November 8th. The stock was sold at an average price of $341.06, for a total transaction of $1,576,379.32. Following the sale, the insider now owns 10,621 shares in the company, valued at approximately $3,622,398.26. The disclosure for this sale can be found here. 0.60% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION NOTICE: “Humana Inc (HUM) Holdings Trimmed by University of Notre Dame DU Lac” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/humana-inc-hum-holdings-trimmed-by-university-of-notre-dame-du-lac/2662848.html.

Humana Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

Recommended Story: Correction

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.